EW Edwards Lifesciences Corporation Common Stock
$92,49
Preço · Ago 19, 2026
Fundamentais a partir de Ago 4, 2026
Intervalo 52 Semanas
$72–$96
84% of range
Classificação do Analista
BUY
40 analysts
Preço-Alvo
$101
+9% upside
P/E (TTM)
57.4
ROE
10.6%
Margem de Lucro Líquido
17.7%
Sobre Edwards Lifesciences Corporation Common Stock Visão geral da empresa da Wikipedia
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
Ler mais
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
History
Edwards Lifesciences was originally founded by electrical engineer Miles "Lowell" Edwards in 1958, a graduate of Oregon State University. Edwards invented the first medically proven and adopted artificial heart valve. Dr. Albert Starr, a surgeon at the Oregon Health and Sciences University, is credited as the first to successfully implant the Starr-Edwards mitral valve in a patient in 1960. As a result of the successful heart implant, Edwards established manufacturing in Santa Ana, California the same year to continue his research in pulmonary devices.
Edwards' valves are still in operation today. An early patient lived a record 48 years with the implant before requiring a replacement.
Edwards was acquired by Baxter in 1985. It was spun off from Baxter in 2000.
In 2017, Edwards completed the acquisition of Valtech Cardio for $340 million. Also in 2017, Edwards acquired Harpoon Medical of Baltimore, Maryland for $100 million. Harpoon, founded in 2013, developed a minimally invasive heart surgery product for mitral valve repair to treat degenerative mitral regurgitation. At the time of the acquisition, the product was not available on any market.
On April 18, 2019, Edwards completed the acquisition of CAS Medical Systems of Branford, Connecticut for ~$100 million.
Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valve systems were FDA-approved for the treatment of patients at low risk for death or major complications associated with open-heart surgery on August 16, 2019. These products are used to treat patients with severe aortic stenosis without utilizing open-heart surgery.
In 2020, Edwards co-sponsored the Virtual ISPOR-FDA Summit centered on patient preference information in medical device regulatory decisions.
In December 2021, the FDA approved the SAPIEN 3 transcatheter valve in combination with the Alterra adaptive prestent for the treatment of severe pulmonary regurgitation.
In February 2024, the FDA approved Edwards' EVOQUE tricuspid valve replacement system, the first transcatheter therapy approved in the United States for the treatment of tricuspid regurgitation. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
In June 2024, the company received FDA approval for a new implant designed to manage heart failure issues, called the Cordella pulmonary artery sensor.
In July 2024, Edwards made agreements with Affluent Medical for an equity stake, IP licensing and an exclusive option to acquire its Kephalios subsidiary. The same month, Edwards announced it would acquire Innovalve Bio Medical for approximately $300 million, and JenaValve Technology and Endotronix for $1.2 billion.
In August 2024, Edwards acquired JC Medical from Genesis MedTech, gaining its J-Valve transcatheter aortic valve replacement system for the treatment of aortic regurgitation.
In 2023, Edwards announced that its critical care business unit would be spun off into a separate entity. In June 2024 Edwards instead agreed to sell the unit to BD for $4.2 billion. The sale closed on September 3, 2024.
In May 2025, the FDA approved the SAPIEN 3 platform, including the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA valves, for the treatment of severe aortic stenosis in asymptomatic patients, marking the first FDA approval of TAVR therapy for this patient population.
In September 2025, Edwards completed the full acquisition of heart failure monitoring company Vectorious Medical Technologies.
In January 2026, the FDA approved the SAPIEN M3 mitral valve replacement system, the first transcatheter mitral valve replacement therapy using a transseptal approach to receive FDA approval for the treatment of mitral regurgitation.
Business segments
Prior to September 2024, its products were categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and critical care. In September 2024, Edwards completed the sale of its Critical Care product group to BD. Since September 2024, its products are categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and implantable heart failure management (IHFM).
Transcatheter Heart Valve
The company's SAPIEN family of transcatheter aortic heart valves is made of bovine pericardial tissue mounted within a balloon-expandable, cobalt-chromium frame and is deployed via catheter. Edwards introduced the transcatheter heart valve replacement procedure to U.S. patients unable to undergo open-heart surgery with FDA approval of the SAPIEN transcatheter valve in 2011. The indication was expanded in November 2012 to include patients at a high risk for death or serious complications associated with open-heart surgery. In 2021, the FDA cleared Edwards’ SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for pulmonic heart valve replacement. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
Transcatheter Mitral and Tricuspid Therapies
The Transcatheter Mitral and Tricuspid Therapies business segment develops transcatheter heart valve repair and replacement technologies to treat mitral and tricuspid valve diseases. In September 2022, the FDA approved Edwards' PASCAL Precision transcatheter valve repair system for the treatment of degenerative mitral regurgitation.
Surgical
The Surgical business segment involves the use of Edwards' RESILIA tissue technology, developed to help limit valve calcification. Edwards estimates that more than 450,000 patients around the world have either undergone SAVR or TAVR with an Edwards RESILIA valve.
Critical Care
Before its sale, the Critical Care business segment included pulmonary artery catheters, disposable pressure transducers and advanced hemodynamic monitoring systems. The portfolio also included a line of balloon catheter-based vascular products, surgical clips and inserts. In 2023, it was announced that the critical care business unit was to be spun off into its own entity, however in 2024 the critical care department was purchased by BD for $4.2 billion.
Organizational culture
Edwards Lifesciences Foundation
The Edwards Lifesciences Foundation launched in 2014 and supports programs designed to treat underserved people to reduce heart valve disease.
Since the initiative launched in 2014, Edwards and its foundation have contributed more than $100 million in financial and technology donations through "Every Heartbeat Matters" (EHM), reaching over 4 million underserved structural heart patients globally.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
EW Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$92.49
Capitalização de Mercado
$61.04B
P/E (TTM)
57.4
EPS (TTM)
$1.83
Receita (TTM)
$6.07B
Rendimento div.
—
ROE
10.6%
Dívida/Capital
0.1
Intervalo 52 Semanas
$72 – $96
EW Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$6.07B
2016-12-31
→
2025-12-31
EPS
$1.83
2016-12-31
→
2025-12-31
Fluxo de caixa livre
$1.33B
2016-12-31
→
2025-12-31
Margens
17.7%
2016-12-31
→
2025-12-31
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
EW
Mediana de Pares
P/E (TTM)
57.4
26.3
P/S (TTM)
10.1
4.4
P/B
5.9
5.3
EV / EBITDA
40.4
—
Price / FCF (Preço / FCF)
45.7
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
EW
Mediana de Pares
Gross Margin (Margem Bruta)
78.0%
63.1%
Operating Margin (Margem Operacional)
20.8%
—
Net Profit Margin (Margem de Lucro Líquido)
17.7%
15.6%
ROA
8.0%
7.6%
ROE
10.6%
15.0%
ROIC
9.6%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
EW
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
0.1
—
Current Ratio (Índice de liquidez corrente)
3.7
1.7
Quick Ratio (Índice de Liquidez Seca)
2.7
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
EW
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
11.6%
—
Revenue CAGR 3Y (CAGR Receita 3A)
10.8%
—
Revenue CAGR 5Y (CAGR Receita 5A)
6.7%
—
EPS YoY
-73.7%
—
Net Income YoY (Lucro Líquido Ano a Ano)
-74.3%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
EW
Mediana de Pares
EW Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
40 analistas
- Compra forte 13 32,5%
- Compra 17 42,5%
- Manter 10 25,0%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
26 analistas · 2026-08-19
Mediana
$101.50
Agora
$92.49
Mín
$84.00
Máx
$110.00
Alvo mediano
$101.50
+9,7%
Alvo médio
$100.96
+9,2%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.02%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $0.78 | $0.76 | 0.02% |
| 31 de Março de 2026 | $0.78 | $0.75 | 0.03% |
| 31 de Dezembro de 2025 | $0.58 | $0.64 | -0.06% |
| 30 de Setembro de 2025 | $0.67 | $0.61 | 0.06% |
| 30 de Junho de 2025 | $0.67 | $0.64 | 0.03% |
| 31 de Março de 2025 | $0.64 | $0.61 | 0.03% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | — |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | — | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| BDX | — | 25.3 | 8.2% | 7.7% | 6.5% | — |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| GEHC | — | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Cost of Revenue | $1.33B | $1.12B | $978M | $724M | $1.25B | $1.08B | $1.11B | $939M | $875M | $797M | $617M | $626M | |
| Gross Profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B | $2.56B | $2.17B | $1.88B | $1.70B | |
| R&D Expense | $1.08B | $1.05B | $963M | $844M | $903M | $761M | $753M | $622M | $553M | $442M | $383M | $346M | |
| SG&A Expense | $2.09B | $1.79B | $1.58B | $1.36B | $1.49B | $1.23B | $1.24B | $1.09B | $991M | $905M | $851M | $858M | |
| Operating Income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $898M | $1.15B | $748M | $1.09B | $751M | · | · | |
| Interest Expense | · | · | $18M | $19M | $18M | $16M | $21M | $30M | $23M | $19M | $17M | $17M | |
| Interest Income | $169M | $120M | $67M | $36M | $17M | $23M | $32M | $32M | $20M | $11M | $8M | $6M | |
| Other Non-op | $7M | $69M | $14M | $5M | $13M | $12M | $8M | $4M | $-1M | $-5M | $-4M | $-8M | |
| Pretax Income | $1.27B | $1.55B | $1.37B | $1.52B | $1.70B | $917M | $1.17B | $761M | $1.03B | $738M | $622M | $1.14B | |
| Income Tax | $217M | $152M | $152M | $196M | $199M | $93M | $120M | $39M | $451M | $168M | $128M | $333M | |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | · | · | · | · | · | · | · | |
| EPS (Basic) | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 | $1.32 | $1.68 | $1.15 | $2.77 | $2.67 | $2.30 | $3.81 | |
| EPS (Diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $2.70 | $2.61 | $2.25 | $3.74 | |
| Shares (Basic) | 584,800,000 | 597,700,000 | 606,700,000 | 619,000,000 | 623,300,000 | 622,600,000 | 624,800,000 | 627,600,000 | 210,900,000 | 213,000,000 | 215,500,000 | 213,000,000 | |
| Shares (Diluted) | 585,800,000 | 599,300,000 | 609,400,000 | 624,200,000 | 631,200,000 | 631,900,000 | 636,700,000 | 640,900,000 | 215,900,000 | 217,800,000 | 220,300,000 | 217,000,000 | |
| EBITDA | $1.42B | $1.53B | $1.68B | $1.89B | $1.83B | $1.00B | $1.24B | $826M | $82M | $71M | $66M | $69M |
Balanço Patrimonial 29
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.94B | $3.05B | $1.13B | $769M | $863M | $1.18B | $1.18B | $714M | $818M | $930M | $718M | $654M | |
| Short-term Investments | $1.29B | $931M | $500M | $446M | $604M | $219M | $338M | $242M | $519M | $341M | $506M | $785M | |
| Receivables | $660M | $609M | $772M | $643M | $582M | $515M | $544M | $457M | $439M | $366M | $315M | $288M | |
| Inventory | $1.13B | $1.09B | $904M | $876M | $727M | $802M | $641M | $607M | $555M | $397M | $340M | $297M | |
| Prepaid Expense | $135M | $121M | $129M | $110M | $85M | $75M | $59M | $54M | $61M | $46M | $45M | $49M | |
| Other Current Assets | $339M | $348M | $225M | $196M | $237M | $208M | $168M | $132M | $117M | $112M | $66M | $122M | |
| Current Assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B | $3.09B | $2.98B | $2.29B | $2.55B | $2.24B | $2.05B | $2.23B | |
| PP&E (Net) | $1.81B | $1.69B | $1.59B | $1.63B | $1.55B | $1.40B | $1.06B | $868M | $680M | $580M | $482M | $443M | |
| PP&E (Gross) | $2.66B | $2.48B | $2.29B | $2.38B | $2.20B | $1.99B | $1.57B | $1.32B | $1.09B | $961M | $854M | $808M | |
| Accum. Depreciation | $850M | $794M | $699M | $750M | $655M | $598M | $512M | $455M | $412M | $381M | $372M | $365M | |
| Goodwill | $1.77B | $1.78B | $1.15B | $1.06B | $1.17B | $1.17B | $1.17B | $1.11B | $1.13B | $626M | $628M | $376M | |
| Intangibles | $1.13B | $1.18B | $399M | $285M | $324M | $331M | $336M | $343M | $468M | $205M | $205M | $23M | |
| Other Non-current Assets | $730M | $722M | $463M | $299M | $111M | $120M | $102M | $34M | $109M | $123M | $132M | $49M | |
| Total Assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Accounts Payable | $228M | $197M | $187M | $202M | $204M | $196M | $180M | $134M | $117M | $97M | $64M | $58M | |
| Current Liabilities | $1.81B | $1.51B | $1.20B | $1.02B | $1.03B | $894M | $902M | $877M | $1.42B | $532M | $476M | $426M | |
| Capital Leases | $83M | $79M | $65M | $70M | $69M | $73M | $59M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $37M | · | · | · | · | · | |
| Other Non-current Liabilities | $362M | $373M | $251M | $218M | $267M | $252M | $203M | $150M | $147M | $115M | $285M | $113M | |
| Total Liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B | $2.66B | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | $594M | $1.04B | $822M | · | · | |
| Total Debt | $598M | $598M | $597M | $596M | $596M | $595M | $594M | $594M | $1.04B | $822M | $600M | $598M | |
| Common Stock | $659M | $655M | $650M | $646M | $642M | $636M | $218M | $215M | $212M | $243M | $239M | $129M | |
| Retained Earnings | $14.24B | $13.17B | $8.99B | $7.59B | $6.07B | $4.57B | $3.74B | $2.69B | $1.96B | $3.91B | $3.34B | $2.84B | |
| Treasury Stock | $7.09B | $6.19B | $5.02B | $4.14B | $2.42B | $1.90B | $1.28B | $1.02B | $252M | $2.50B | $1.84B | $1.56B | |
| AOCI | $-238M | $-244M | $-243M | $-255M | $-158M | $-161M | $-156M | $-138M | $-133M | $-198M | $-183M | $-101M | |
| Stockholders' Equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B | $4.57B | $4.15B | $3.14B | $2.96B | $2.62B | $2.50B | $2.19B | |
| Liabilities + Equity | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Shares Outstanding | 580,700,000 | 654,800,000 | 650,500,000 | 646,300,000 | 642,000,000 | 636,400,000 | 218,100,000 | 207,700,000 | 209,700,000 | 211,600,000 | 215,400,000 | 107,800,000 |
Fluxo de Caixa 18
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $157M | $155M | $145M | $140M | $135M | $107M | $89M | $77M | $82M | $71M | $66M | $69M | |
| Stock-based Comp | $158M | $162M | $139M | $127M | $109M | $93M | $81M | $71M | $62M | $57M | $50M | $48M | |
| Deferred Tax | $-66M | $-163M | $-242M | $-262M | $-44M | $-52M | $10M | $-21M | $27M | $-24M | $-16M | $-67M | |
| Amort. of Intangibles | $8M | $6M | $2M | $2M | $8M | $5M | $5M | $2M | $8M | $8M | $7M | $8M | |
| Restructuring | $13M | $33M | · | · | · | · | · | · | · | · | $0 | $0 | |
| Other Non-cash | $273M | $-3.79B | $-529M | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $1.60B | $542M | $896M | $1.22B | $1.73B | $1.05B | $1.18B | $927M | $1.00B | $704M | $550M | $1.02B | |
| CapEx | $260M | $252M | $253M | $245M | $326M | $407M | $254M | $239M | $168M | $176M | $103M | $83M | |
| Investing Cash Flow | $-713M | $2.31B | $174M | $252M | $-1.72B | $-531M | $-596M | $77M | $-647M | $-212M | $-316M | · | |
| Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Net Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Stock Repurchased | $893M | $1.16B | $880M | $1.73B | $513M | $625M | $263M | $796M | $763M | $662M | $280M | $301M | |
| Net Stock Activity | $-893M | $-1.16B | $-880M | $-1.73B | $-513M | $-625M | $-263M | $-796M | $-763M | $-662M | $-280M | $-301M | |
| Financing Cash Flow | $-957M | $-983M | $-711M | $-1.58B | $-356M | $-487M | $-116M | $-1.10B | $-473M | $-268M | $-159M | · | |
| Net Change in Cash | $-119M | $1.91B | $375M | $-95M | $-333M | $16M | $468M | $-104M | $-112M | $212M | $65M | $233M | |
| Taxes Paid | $490M | $1.20B | $470M | · | · | · | · | · | · | · | · | $275M | |
| Free Cash Flow | $1.33B | $290M | $643M | $974M | $1.41B | $647M | $925M | $688M | $833M | $528M | $447M | $939M | |
| Levered FCF | · | · | $627M | $957M | $1.39B | $633M | $906M | $660M | $820M | $513M | $433M | $927M |
Lucratividade 8
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% | 75.2% | 73.1% | |
| Operating Margin | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% | 20.5% | 26.4% | 20.1% | · | · | · | · | |
| Net Margin | 17.7% | 76.8% | 23.4% | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | 21.0% | 28.5% | 26.6% | 32.8% | 32.5% | 20.9% | 26.8% | 20.4% | 30.1% | 24.9% | 25.0% | 49.2% | |
| EBITDA Margin | 23.4% | 28.2% | 28.0% | 35.1% | 34.9% | 22.9% | 28.4% | 22.2% | 2.4% | 2.4% | 2.6% | 2.9% | |
| ROA | 8.0% | 37.2% | 15.9% | · | · | · | · | · | · | · | · | · | |
| ROE | 10.6% | 50.1% | 22.5% | · | · | · | · | · | · | · | · | · | |
| ROIC | 9.6% | 11.7% | 18.5% | 23.5% | 23.2% | 15.6% | 21.7% | 19.0% | · | · | · | · |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 | 3.5 | 3.3 | 2.6 | 1.8 | 4.2 | 4.3 | 5.3 | |
| Quick Ratio | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 | 2.1 | 2.3 | 1.6 | 1.3 | 3.1 | 3.2 | 4.0 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 | 0.3 | 0.2 | 0.3 | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.2 | 0.3 | |
| Interest Coverage | · | · | 87.2 | 91.1 | 91.9 | 56.8 | 55.4 | 25.0 | · | · | · | · |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.7 | 0.6 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | 1.2 | 1.1 | 1.4 | 1.3 | 1.6 | 1.5 | 1.8 | 1.6 | 1.8 | 2.2 | 1.9 | 2.1 | |
| Receivables Turnover | 9.6 | 7.9 | 8.5 | 8.8 | 9.5 | 8.3 | 8.7 | 8.3 | 8.7 | 8.7 | 8.3 | 7.9 |
Taxas de Crescimento 8
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.6% | 8.6% | 12.2% | -14.7% | 19.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 10.8% | 1.3% | 4.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -73.7% | 203.0% | -5.7% | 2.5% | 83.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -9.1% | 43.1% | 20.9% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -74.3% | 197.7% | -7.8% | 1.2% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -11.0% | 40.6% | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Net Income TTM | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $235M | $235M | $235M | $235M | $235M | $235M | $235M | |
| Market Cap | $49.50B | $43.57B | $45.83B | $45.39B | $80.85B | $56.95B | $16.26B | $10.60B | $7.88B | $6.61B | $5.67B | $2.29B | |
| Enterprise Value | $45.88B | $40.20B | $44.79B | $44.77B | $79.98B | $56.15B | $15.34B | $10.24B | $7.58B | $6.16B | $5.05B | $1.45B | |
| P/E | 46.6 | 10.6 | 33.2 | 30.6 | 54.4 | 70.2 | 47.4 | 45.2 | 13.9 | 12.0 | 11.7 | 5.7 | |
| P/S | 8.2 | 8.0 | 9.1 | 10.2 | 15.5 | 13.0 | 3.7 | 2.8 | 2.3 | 2.2 | 2.3 | 1.0 | |
| P/B | 4.8 | 4.4 | 6.9 | 7.8 | 13.9 | 12.5 | 3.9 | 3.4 | 2.7 | 2.5 | 2.3 | 1.0 | |
| P / Tangible Book | 6.7 | 6.2 | 9.0 | 10.2 | 18.6 | 18.6 | · | · | · | · | · | · | |
| P / Cash Flow | 31.0 | 80.4 | 51.2 | 37.3 | 46.7 | 54.0 | 13.8 | 11.4 | 7.9 | 9.4 | 10.3 | 2.2 | |
| P / FCF | 37.1 | 150.3 | 71.3 | 46.6 | 57.5 | 88.0 | 17.6 | 15.4 | 9.5 | 12.5 | 12.7 | 2.4 | |
| EV / EBITDA | 32.3 | 26.2 | 26.7 | 23.7 | 43.8 | 55.9 | 12.4 | 12.4 | 92.5 | 86.5 | 76.7 | 21.1 | |
| EV / FCF | 34.4 | 138.7 | 69.7 | 46.0 | 56.9 | 86.7 | 16.6 | 14.9 | 9.1 | 11.7 | 11.3 | 1.5 | |
| EV / Revenue | 7.6 | 7.4 | 8.9 | 10.0 | 15.3 | 12.8 | 3.5 | 2.8 | 2.2 | 2.1 | 2.0 | 0.6 | |
| Earnings Yield | 2.1% | 9.4% | 3.0% | 3.3% | 1.8% | 1.4% | 2.1% | 2.2% | 7.2% | 8.4% | 8.6% | 17.6% |
Demonstração de Resultados 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B | $1.35B | $1.37B | $1.33B | $1.01B | $1.24B | $1.28B | $1.22B | $430M | $1.32B | |
| Cost of Revenue | $392M | $363M | $343M | $345M | $344M | $302M | $292M | $263M | $276M | $287M | $141M | $251M | $257M | $330M | $-99M | $254M | |
| Gross Profit | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B | $1.09B | $1.09B | $1.04B | $870M | $993M | $1.03B | $992M | $529M | $1.07B | |
| R&D Expense | $279M | $263M | $268M | $281M | $276M | $255M | $271M | $253M | $272M | $257M | $215M | $243M | $244M | $261M | $131M | $234M | |
| SG&A Expense | $561M | $522M | $603M | $515M | $502M | $466M | $492M | $421M | $448M | $428M | $354M | $382M | $410M | $436M | $201M | $377M | |
| Operating Income | $513M | $478M | $151M | $307M | $411M | $395M | $313M | $351M | $366M | $349M | $291M | $366M | $264M | $388M | $198M | $402M | |
| Interest Income | $30M | $34M | · | · | $37M | $36M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $17M | $72M | $3M | $3M | $-1M | $3M | $33M | $28M | $2M | $6M | $3M | $7M | $2M | $2M | $6M | $-2M | |
| Pretax Income | $520M | $459M | $90M | $348M | $400M | $434M | $390M | $403M | $384M | $371M | $311M | $388M | $275M | $399M | $211M | $407M | |
| Income Tax | $278M | $78M | $26M | $56M | $64M | $70M | $45M | $41M | $20M | $46M | $21M | $53M | $21M | $58M | $11M | $64M | |
| Net Income | $242M | $381M | $91M | $291M | $333M | $358M | $386M | $3.07B | $366M | $352M | $370M | $385M | $307M | $340M | $398M | $344M | |
| EPS (Basic) | $0.42 | $0.66 | $0.16 | $0.50 | $0.57 | $0.61 | $0.65 | $5.14 | $0.61 | $0.58 | $0.61 | $0.63 | $0.51 | $0.56 | $0.66 | $0.55 | |
| EPS (Diluted) | $0.42 | $0.66 | $0.16 | $0.50 | $0.56 | $0.61 | $0.65 | $5.13 | $0.61 | $0.58 | $0.61 | $0.63 | $0.50 | $0.56 | $0.65 | $0.55 | |
| Shares (Basic) | 576,400,000 | 579,200,000 | -1,173,800,000 | 584,700,000 | 587,000,000 | 586,900,000 | -1,203,200,000 | 597,200,000 | 602,100,000 | 601,600,000 | -1,214,700,000 | 607,000,000 | 606,900,000 | 607,500,000 | -1,243,800,000 | 619,800,000 | |
| Shares (Diluted) | 577,600,000 | 580,700,000 | -1,175,600,000 | 585,700,000 | 587,900,000 | 587,800,000 | -1,207,200,000 | 598,100,000 | 604,300,000 | 604,100,000 | -1,221,300,000 | 609,500,000 | 610,300,000 | 610,900,000 | -1,256,400,000 | 624,500,000 | |
| EBITDA | $513M | $518M | · | $307M | $411M | $431M | · | $351M | $369M | $426M | · | $418M | $327M | $424M | · | $402M |
Balanço Patrimonial 27
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.91B | $2.45B | $2.94B | $2.69B | $3.27B | $3.14B | $3.05B | $3.68B | $1.64B | $1.22B | · | $1.41B | $1.04B | $872M | · | $1.25B | |
| Short-term Investments | $1.35B | $1.23B | $1.29B | $1.16B | $789M | $758M | $931M | $770M | $345M | $473M | · | $454M | $467M | $382M | · | $491M | |
| Receivables | $770M | $776M | $660M | $693M | $697M | $669M | $609M | $716M | $778M | $818M | · | $740M | $754M | $718M | · | $618M | |
| Inventory | $1.13B | $1.12B | $1.13B | $1.14B | $1.14B | $1.11B | $1.09B | $1.10B | $1.02B | $1.21B | · | $1.03B | $980M | $914M | · | $758M | |
| Prepaid Expense | $119M | $136M | $135M | $125M | $110M | $111M | $121M | $115M | $110M | $138M | · | $133M | $123M | $119M | · | $88M | |
| Other Current Assets | $360M | $330M | $339M | $323M | $314M | $304M | $348M | $231M | $252M | $251M | · | $236M | $217M | $190M | · | $268M | |
| Current Assets | $6.82B | $6.23B | $6.74B | $6.36B | $6.58B | $6.21B | $6.29B | $6.73B | $4.52B | $4.17B | · | $4.07B | $3.65B | $3.26B | · | $3.51B | |
| PP&E (Net) | $1.84B | $1.82B | $1.81B | $1.74B | $1.73B | $1.70B | $1.69B | $1.68B | $1.64B | $1.77B | · | $1.68B | $1.66B | $1.65B | · | $1.57B | |
| PP&E (Gross) | · | · | $2.66B | · | · | · | $2.48B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $850M | · | · | · | $794M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $1.95B | $1.82B | $1.77B | $1.77B | $1.78B | $1.78B | $1.78B | $1.61B | $1.15B | $1.25B | $1.15B | $1.30B | $1.30B | $1.31B | $1.06B | $1.16B | |
| Intangibles | $1.38B | $1.23B | $1.13B | $1.13B | $1.17B | $1.17B | $1.18B | $956M | $417M | $447M | · | $430M | $431M | $447M | · | $266M | |
| Other Non-current Assets | $616M | $739M | $730M | $785M | $743M | $743M | $722M | $684M | $790M | $768M | · | $447M | $412M | $294M | · | $316M | |
| Total Assets | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Accounts Payable | $210M | $181M | $228M | $165M | $162M | $172M | $197M | $173M | $186M | $212M | · | $191M | $193M | $181M | · | $155M | |
| Current Liabilities | $1.51B | $1.41B | $1.81B | $1.59B | $1.40B | $1.39B | $1.51B | $1.94B | $1.22B | $1.11B | · | $1.24B | $1.16B | $1.08B | · | $918M | |
| Capital Leases | $82M | $80M | $83M | $75M | $79M | $78M | $79M | $85M | $74M | $77M | · | $70M | $64M | $66M | · | $67M | |
| Other Non-current Liabilities | $382M | $351M | $362M | $363M | $379M | $358M | $373M | $323M | $257M | $266M | · | $240M | $243M | $260M | · | $221M | |
| Total Liabilities | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | $2.83B | $2.99B | $3.36B | $2.59B | $2.55B | · | $2.64B | $2.56B | $2.59B | · | $2.42B | |
| Total Debt | $599M | $598M | · | $598M | $598M | $598M | · | $598M | $597M | $597M | · | $597M | $597M | $596M | · | $596M | |
| Common Stock | $662M | $660M | $659M | $658M | $658M | $656M | $655M | $654M | $654M | $652M | · | $650M | $649M | $647M | · | $646M | |
| Retained Earnings | $14.86B | $14.62B | $14.24B | $14.15B | $13.86B | $13.53B | $13.17B | $12.78B | $9.71B | $9.34B | · | $8.62B | $8.24B | $7.93B | · | $7.19B | |
| Treasury Stock | $7.67B | $7.51B | $7.09B | $7.05B | $6.46B | $6.45B | $6.19B | $6.09B | $5.18B | $5.02B | · | $4.58B | $4.40B | $4.39B | · | $3.28B | |
| AOCI | $-215M | $-221M | $-238M | $-250M | $-264M | $-254M | $-244M | $-252M | $-220M | $-233M | · | $-250M | $-256M | $-255M | · | $-256M | |
| Stockholders' Equity | $10.62B | $10.33B | $10.34B | $10.21B | $10.55B | $10.13B | $10.00B | $9.55B | $7.44B | $7.12B | · | $6.66B | $6.38B | $5.98B | · | $6.22B | |
| Liabilities + Equity | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Shares Outstanding | 576,600,000 | 577,000,000 | 580,700,000 | 580,700,000 | 587,900,000 | 586,200,000 | 588,600,000 | 589,800,000 | 602,300,000 | 602,400,000 | 650,500,000 | 606,500,000 | 607,900,000 | 606,000,000 | 646,300,000 | 619,400,000 |
Fluxo de Caixa 13
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $43M | $41M | $43M | $39M | $38M | $37M | $43M | $34M | $40M | $38M | $37M | $37M | $36M | $35M | $35M | $35M | |
| Stock-based Comp | $42M | $45M | $39M | $41M | $38M | $40M | $32M | $42M | $44M | $45M | $30M | $33M | $37M | $39M | $28M | $30M | |
| Restructuring | · | · | $5M | $100.0K | · | · | $0 | $33M | · | · | · | $0 | · | · | · | · | |
| Other Non-cash | · | $-423M | · | · | · | $-154M | · | · | · | $-488M | · | · | · | · | · | · | |
| Operating Cash Flow | $652M | $44M | $451M | $574M | $290M | $280M | $-128M | $352M | $372M | $-54M | $137M | $412M | $34M | $314M | $283M | $310M | |
| CapEx | $67M | $65M | $97M | $58M | $49M | $56M | $50M | $52M | $85M | $65M | $88M | $55M | $48M | $62M | $69M | $60M | |
| Investing Cash Flow | $-193M | $-93M | $-198M | $-428M | $-172M | $85M | $-577M | $2.70B | $125M | $63M | $14M | $89M | $70M | $500.0K | $95M | $-202M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | $153M | $422M | $41M | $589M | $6M | $259M | $100M | $901M | $158M | $200.0K | $448M | $174M | $8M | $249M | $866M | $100M | |
| Net Stock Activity | · | $-422M | · | · | · | $-259M | · | · | · | $-200.0K | · | · | · | $-249M | · | · | |
| Financing Cash Flow | $-300.0K | $-451M | $-11M | $-740M | $53M | $-258M | $29M | $-977M | $-97M | $62M | $-413M | $-143M | $52M | $-207M | $-838M | $-70M | |
| Net Change in Cash | $462M | $-492M | $245M | $-595M | $141M | $90M | $-625M | $2.03B | $429M | $81M | $-266M | $366M | $171M | $104M | $-479M | $49M | |
| Free Cash Flow | · | $-21M | · | · | · | $224M | · | · | · | $-119M | · | · | · | $253M | · | · |
Lucratividade 8
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 78.0% | · | 77.8% | 77.5% | 78.6% | · | 80.6% | 79.4% | 75.9% | · | 76.3% | 77.6% | 77.4% | · | 80.8% | |
| Operating Margin | 29.5% | 29.0% | · | 19.8% | 26.8% | 28.0% | · | 25.9% | 26.6% | 24.2% | · | 28.2% | 21.4% | 26.6% | · | 30.5% | |
| Net Margin | 13.9% | 23.1% | · | 18.7% | 21.8% | 25.3% | · | 226.7% | 26.4% | 22.0% | · | 26.0% | 20.1% | · | · | · | |
| Pretax Margin | 29.9% | 27.8% | · | 22.4% | 26.1% | 30.7% | · | 29.7% | 27.9% | 25.6% | · | 29.7% | 22.1% | 27.3% | · | 30.9% | |
| EBITDA Margin | 29.5% | 31.4% | · | 19.8% | 26.8% | 30.5% | · | 25.9% | 26.6% | 26.7% | · | 28.2% | 21.4% | 29.0% | · | 30.5% | |
| ROA | 1.8% | 2.9% | · | 2.2% | 2.8% | 3.1% | · | 27.5% | 3.8% | 3.8% | · | 4.3% | 3.5% | · | · | · | |
| ROE | 2.3% | 3.7% | · | 2.9% | 3.7% | 4.2% | · | 37.9% | 5.3% | 5.4% | · | 6.0% | 5.0% | · | · | · | |
| ROIC | 2.1% | 3.6% | · | 2.4% | 3.1% | 3.1% | · | 3.1% | 4.3% | 4.3% | · | 5.0% | 4.2% | 5.1% | · | 5.0% |
Liquidez e Solvência 4
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 4.4 | · | 4.0 | 4.7 | 4.5 | · | 3.5 | 3.7 | 3.8 | · | 3.3 | 3.2 | 3.0 | · | 3.8 | |
| Quick Ratio | 3.3 | 3.2 | · | 2.9 | 3.4 | 3.3 | · | 2.7 | 2.3 | 2.3 | · | 2.1 | 2.0 | 1.8 | · | 2.6 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | 2.4 | 2.3 | · | 2.2 | 2.1 | 1.9 | · | 1.9 | 1.8 | 2.1 | · | 2.2 | 2.2 | 2.2 | · | 2.2 |
Avaliação (TTM) 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.47B | $6.15B | · | $5.88B | $5.69B | $5.52B | · | $5.32B | $5.21B | $5.12B | · | $5.06B | $5.19B | $5.26B | · | $5.34B | |
| Net Income TTM | $1.25B | $1.36B | · | $1.37B | $4.15B | $4.18B | · | $4.16B | $1.47B | $1.41B | · | $1.38B | $1.40B | · | · | · | |
| Market Cap | $52.16B | $46.21B | · | $45.16B | $45.98B | $42.49B | · | $38.92B | $55.63B | $57.57B | · | $42.02B | $57.34B | $50.13B | · | $51.18B | |
| Enterprise Value | $48.51B | $43.13B | · | $41.92B | $42.52B | $39.19B | · | $35.07B | $54.24B | $56.46B | · | $40.75B | $56.43B | $49.48B | · | $50.04B | |
| P/E | 42.3 | 34.4 | · | 33.5 | 11.3 | 10.4 | · | 9.5 | 38.0 | 41.2 | · | 30.9 | 41.7 | 35.2 | · | 35.5 | |
| P/S | 8.1 | 7.5 | · | 7.7 | 8.1 | 7.7 | · | 7.3 | 10.7 | 11.2 | · | 8.3 | 11.0 | 9.5 | · | 9.6 | |
| P/B | 4.9 | 4.5 | · | 4.4 | 4.4 | 4.2 | · | 4.1 | 7.5 | 8.1 | · | 6.3 | 9.0 | 8.4 | · | 8.2 | |
| P / Tangible Book | 7.2 | 6.3 | · | 6.2 | 6.1 | 5.9 | · | 5.6 | 9.5 | 10.6 | · | 8.5 | 12.3 | 11.9 | · | 10.7 | |
| P / Cash Flow | · | 1054.9 | · | · | · | 151.5 | · | · | · | -1076.0 | · | · | · | 159.6 | · | · | |
| P / FCF | · | -2189.9 | · | · | · | 189.3 | · | · | · | -484.6 | · | · | · | 198.5 | · | · | |
| EV / EBITDA | 94.5 | 83.2 | · | 136.5 | 103.4 | 90.8 | · | 100.0 | 147.0 | 132.5 | · | 97.4 | 172.5 | 116.8 | · | 124.4 | |
| EV / FCF | · | -2044.2 | · | · | · | 174.6 | · | · | · | -475.3 | · | · | · | 195.9 | · | · | |
| EV / Revenue | 7.5 | 7.0 | · | 7.1 | 7.5 | 7.1 | · | 6.6 | 10.4 | 11.0 | · | 8.0 | 10.9 | 9.4 | · | 9.4 | |
| Earnings Yield | 2.4% | 2.9% | · | 3.0% | 8.9% | 9.7% | · | 10.5% | 2.6% | 2.4% | · | 3.2% | 2.4% | 2.8% | · | 2.8% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| Margem Bruta % | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% |
| Margem Operacional % | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% |
| Lucro líquido | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| EPS Diluído | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Índice de liquidez corrente | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 |
| Índice de Liquidez Seca | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $1.33B | $290M | $643M | $974M | $1.41B |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 1.442 declarantes · $30.2B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 152 (+6 vs trimestre anterior) | 97 (-10 vs trimestre anterior) | 459 (+11 vs trimestre anterior) | 452 (+4 vs trimestre anterior) | +26.4M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3.402.739.018 | 37.615.952 | 11,25% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.389.175.425 | 26.411.402 | 7,90% | Ações |
| STATE STREET CORP | $2.381.082.692 | 26.321.940 | 7,87% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $1.430.999.585 | 15.819.142 | 4,73% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $1.219.437.867 | 13.541.730 | 4,03% | Ações |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1.135.640.991 | 12.554.068 | 3,75% | Ações |
| Ninety One UK Ltd | $1.116.050.276 | 12.337.502 | 3,69% | Ações |
| Aristotle Capital Management, LLC | $783.906.442 | 8.665.712 | 2,59% | Ações |
| NORGES BANK | $757.492.410 | 8.373.783 | 2,50% | Ações |
| ALLIANCEBERNSTEIN L.P. | $693.526.113 | 8.660.416 | 2,29% | Ações |
| FMR LLC | $607.177.379 | 6.712.109 | 2,01% | Ações |
| Artisan Partners Limited Partnership | $599.361.052 | 6.625.703 | 1,98% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $513.572.538 | 5.677.344 | 1,70% | Ações |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | $434.208.000 | 4.800.000 | 1,44% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $334.052.859 | 3.692.824 | 1,10% | Ações |
| MILLENNIUM MANAGEMENT LLC | $324.280.556 | 3.584.795 | 1,07% | Ações |
| CITADEL ADVISORS LLC | $308.338.066 | 3.408.557 | 1,02% | Ações |
| PRIMECAP MANAGEMENT CO/CA/ | $308.314.004 | 3.408.291 | 1,02% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $298.865.427 | 3.303.843 | 0,99% | Ações |
| BROWN ADVISORY INC | $295.062.880 | 3.261.805 | 0,98% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $292.399.738 | 3.232.365 | 0,97% | Ações |
| Holocene Advisors, LP | $283.979.721 | 3.139.285 | 0,94% | Ações |
| NEUBERGER BERMAN GROUP LLC | $255.069.412 | 2.818.763 | 0,84% | Ações |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $250.776.107 | 2.772.232 | 0,83% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $238.277.000 | 2.634.054 | 0,79% | Ações |
| Mirova US LLC | $229.802.865 | 2.540.381 | 0,76% | Ações |
| BANK OF AMERICA CORP /DE/ | $170.884.489 | 1.889.061 | 0,56% | Ações |
| BlackRock, Inc. | $168.018.323 | 1.857.377 | 0,56% | Ações |
| Assenagon Asset Management S.A. | $163.997.286 | 1.812.926 | 0,54% | Ações |
| Point72 Asset Management, L.P. | $160.486.895 | 1.774.120 | 0,53% | Ações |
| RAYMOND JAMES FINANCIAL INC | $152.806.000 | 1.689.211 | 0,51% | Ações |
| Swiss National Bank | $147.097.006 | 1.626.100 | 0,49% | Ações |
| Woodline Partners LP | $141.123.209 | 1.560.062 | 0,47% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $140.351.128 | 1.551.434 | 0,46% | Ações |
| TWO SIGMA INVESTMENTS, LP | $137.670.984 | 1.521.899 | 0,46% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $131.472.173 | 1.453.357 | 0,43% | Ações |
| Mitsubishi UFJ Asset Management Co., Ltd. | $126.120.870 | 1.394.217 | 0,42% | Ações |
| Legal & General Group Plc | $121.108.845 | 1.338.811 | 0,40% | Ações |
| ROYAL BANK OF CANADA | $119.193.000 | 1.317.637 | 0,39% | Ações |
| Sumitomo Mitsui Trust Group, Inc. | $113.885.341 | 1.258.958 | 0,38% | Ações |
| Quantinno Capital Management LP | $113.292.795 | 1.252.407 | 0,37% | Ações |
| Vanguard Global Advisers, LLC | $112.247.472 | 1.240.852 | 0,37% | Ações |
| VANGUARD GROUP INC | $107.656.172 | 1.262.829 | 0,36% | Ações |
| SEB Asset Management AB | $106.981.085 | 1.182.636 | 0,35% | Ações |
| Liontrust Investment Partners LLP | $106.083.480 | 1.244.381 | 0,35% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $100.522.409 | 1.111.236 | 0,33% | Ações |
| Polar Capital Holdings Plc | $99.945.636 | 1.104.860 | 0,33% | Ações |
| RHUMBLINE ADVISERS | $99.213.696 | 1.096.770 | 0,33% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $92.822.996 | 1.026.122 | 0,31% | Ações |
| PARNASSUS INVESTMENTS, LLC | $91.873.890 | 1.015.630 | 0,30% | Ações |
| Bank of New York Mellon Corp | $91.654.072 | 1.013.200 | 0,30% | Ações |
| National Pension Service | $90.349.187 | 998.775 | 0,30% | Ações |
| California Public Employees Retirement System | $89.091.250 | 984.869 | 0,29% | Ações |
| Caisse de depot et placement du Quebec | $87.523.397 | 967.537 | 0,29% | Ações |
| ABN AMRO Bank N.V. | $83.573.385 | 924.314 | 0,28% | Ações |
| GOLDMAN SACHS GROUP INC | $82.454.109 | 911.498 | 0,27% | Ações |
| Empower Advisory Group, LLC | $80.384.543 | 888.620 | 0,27% | Ações |
| Meridiem Capital Partners LP | $77.697.994 | 858.921 | 0,26% | Ações |
| Man Group plc | $76.372.212 | 844.265 | 0,25% | Ações |
| ORBIMED ADVISORS LLC | $75.525.054 | 834.900 | 0,25% | Ações |
| Alyeska Investment Group, L.P. | $73.531.316 | 812.860 | 0,24% | Ações |
| Nantahala Capital Management, LLC | $72.368.000 | 800.000 | 0,24% | Opção de venda |
| CANADA PENSION PLAN INVESTMENT BOARD | $72.254.020 | 798.740 | 0,24% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $69.805.736 | 871.700 | 0,23% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $66.940.606 | 740.002 | 0,22% | Ações |
| Bellevue Group AG | $66.871.108 | 739.234 | 0,22% | Ações |
| Birch Hill Investment Advisors LLC | $66.522.203 | 735.377 | 0,22% | Ações |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $64.772.074 | 716.030 | 0,21% | Ações |
| TD Asset Management Inc | $61.560.472 | 680.527 | 0,20% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $61.491.904 | 679.769 | 0,20% | Ações |
| UBS Group AG | $60.908.889 | 673.324 | 0,20% | Ações |
| Candriam S.C.A. | $59.988.129 | 663.784 | 0,20% | Ações |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $57.604.363 | 675.711 | 0,19% | Ações |
| Integral Health Asset Management, LLC | $56.537.500 | 625.000 | 0,19% | Ações |
| Ninety One North America, Inc. | $55.768.413 | 616.498 | 0,18% | Ações |
| Robeco Institutional Asset Management B.V. | $55.270.246 | 610.991 | 0,18% | Ações |
| Seilern Investment Management Ltd | $54.296.896 | 600.231 | 0,18% | Ações |
| Nan Shan Life Insurance Co., Ltd. | $49.953.912 | 552.221 | 0,17% | Ações |
| PFA Pension, Forsikringsaktieselskab | $49.175.025 | 543.611 | 0,16% | Ações |
| BARCLAYS PLC | $49.135.520 | 543.174 | 0,16% | Ações |
| Triodos Investment Management BV | $44.629.165 | 493.358 | 0,15% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $44.266.149 | 489.345 | 0,15% | Ações |
| Mitsubishi UFJ Trust & Banking Corp | $43.182.890 | 477.370 | 0,14% | Ações |
| APG Asset Management N.V. | $42.840.046 | 541.444 | 0,14% | Ações |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $42.480.287 | 469.603 | 0,14% | Ações |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $42.097.461 | 465.371 | 0,14% | Ações |
| AVIVA PLC | $41.577.497 | 459.623 | 0,14% | Ações |
| Balyasny Asset Management L.P. | $41.248.584 | 455.987 | 0,14% | Ações |
| Korea Investment CORP | $40.486.097 | 447.558 | 0,13% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $39.585.296 | 437.600 | 0,13% | Opção de compra |
| NORDEA INVESTMENT MANAGEMENT AB | $37.761.927 | 418.322 | 0,12% | Ações |
| STOREBRAND ASSET MANAGEMENT AS | $37.671.343 | 416.442 | 0,12% | Ações |
| Qube Research & Technologies Ltd | $37.490.061 | 414.438 | 0,12% | Ações |
| OFI INVEST ASSET MANAGEMENT | $36.480.086 | 458.427 | 0,12% | Ações |
| Fisher Funds Management LTD | $35.971.057 | 397.646 | 0,12% | Ações |
| LPL Financial LLC | $34.985.891 | 386.755 | 0,12% | Ações |
| ABN AMRO INVESTMENT SOLUTIONS | $33.668.217 | 372.189 | 0,11% | Ações |
| AMERIPRISE FINANCIAL INC | $32.517.021 | 359.463 | 0,11% | Ações |
| BLAIR WILLIAM & CO/IL | $32.206.687 | 356.032 | 0,11% | Ações |
| Champlain Investment Partners, LLC | $31.357.054 | 346.640 | 0,10% | Ações |
Executivos da empresa 48 insiders · 18 diretores · 8 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Bernard J Zovighian | CEO | 27 de Julho de 2026 S | 8.916 | 0 | 8 | $-6.996.971 |
| Theodora Mistras | CVP, Chief Financial Officer | 9 de Julho de 2026 A | 99.920 | 0 | 0 | $0 |
| Thomas M Abate | CVP, CFO | 14 de Maio de 2013 A | 43.047 | 0 | 0 | $0 |
| Wayne Markowitz | CVP, JAPAC | 30 de Julho de 2026 S | 21.534 | 0 | 4 | $-928.942 |
| Annette Bruls | CVP, EMEACLA | 11 de Julho de 2026 F | 20.628 | 0 | 0 | $0 |
| Andrew M. Dahl | SVP, Corporate Controller | 29 de Maio de 2026 S | 15.334 | 0 | 1 | $-48.893 |
| Carlyn D Solomon | CVP, Critical Care & Vascular | 28 de Outubro de 2014 M | 31.154 | 0 | 0 | $0 |
| Christine Z Mccauley | CVP, Human Resources | 13 de Maio de 2013 F | 4.035 | 0 | 0 | $0 |
| Paul C Redmond | CVP, Global Operations | 13 de Maio de 2013 S | 12.534 | 0 | 0 | $0 |
| Bruce P Garren | CVP, Public Affairs/Special Co | 13 de Maio de 2013 F | 56.071 | 0 | 0 | $0 |
| John H Kehl JR | CVP, Strategy & Corp Dev | 7 de Maio de 2013 F | 101.767 | 0 | 0 | $0 |
| Robert C Reindl | CVP, H.R. and Communications | 27 de Julho de 2012 M | 1.124 | 0 | 0 | $0 |
| Aimee S Weisner | CVP, General Counsel | 9 de Maio de 2012 A | 1.675 | 0 | 0 | $0 |
| Corinne H Nevinny | CVP & Pres., Global Ops | 13 de Maio de 2010 A | 16.687 | 0 | 0 | $0 |
| Anita Bessler | CVP | 31 de Agosto de 2007 S | 29.410 | 0 | 0 | $0 |
| John Alexander Martin | CVP, North America | 10 de Maio de 2007 A | 15.300 | 0 | 0 | $0 |
| Stuart L Foster | CVP, Critical Care / Vascular | 10 de Maio de 2007 A | 24.604 | 0 | 0 | $0 |
| Randel William Woodgrift | Corp VP, Manufacturing Ops | 4 de Agosto de 2005 M | 3.349 | 0 | 0 | $0 |
| John T Cardis | Conselheiro | 10 de Agosto de 2016 S | 91.458 | 0 | 0 | $0 |
| Barbara J Mcneil | Conselheiro | 4 de Fevereiro de 2016 S | 46.454 | 0 | 0 | $0 |
| Robert Alexander Ingram | Conselheiro | 15 de Maio de 2015 A | 32.367 | 0 | 0 | $0 |
| Michael R Bowlin | Conselheiro | 14 de Novembro de 2014 M | 81.751 | 0 | 0 | $0 |
| David E I Pyott | Conselheiro | 9 de Maio de 2014 A | 53.582 | 0 | 0 | $0 |
| NEAL PHILIP M | Conselheiro | 12 de Agosto de 2008 M | 27.333 | 0 | 0 | $0 |
| Vernon R Loucks JR | Conselheiro | 9 de Maio de 2008 A | 24.133 | 0 | 0 | $0 |
| Daniel J. Lippis | — | 11 de Agosto de 2026 M | 40.034 | 0 | 12 | $-817.452 |
| Donald E Bobo JR | — | 27 de Maio de 2026 S | 98.611 | 0 | 12 | $-11.153.294 |
| Daveen Chopra | — | 22 de Maio de 2026 S | 44.324 | 0 | 3 | $-500.535 |
| Scott B. Ullem | — | 11 de Maio de 2026 M | 46.740 | 0 | 7 | $-3.875.008 |
| Leslie C. Davis | — | 8 de Maio de 2026 A | 9.834 | 0 | 0 | $0 |
| Ramona Sequeira | — | 8 de Maio de 2026 A | 6.779 | 0 | 0 | $0 |
| David T Feinberg | — | 8 de Maio de 2026 A | 9.087 | 0 | 0 | $0 |
| Kieran Gallahue | — | 8 de Maio de 2026 A | 4.315 | 0 | 0 | $0 |
| Nicholas J Valeriani | — | 8 de Maio de 2026 A | 84.423 | 0 | 0 | $0 |
| Heisz Leslie Stone | — | 8 de Maio de 2026 A | 34.199 | 0 | 1 | $-218.117 |
| Steven R Loranger | — | 8 de Maio de 2026 A | 8.997 | 0 | 0 | $0 |
| Paul A Laviolette | — | 8 de Maio de 2026 A | 17.552 | 0 | 0 | $0 |
| Larry L Wood | — | 18 de Agosto de 2025 M | 206.900 | 0 | 0 | $0 |
| Catherine M. Szyman | — | 3 de Setembro de 2024 F | 81.287 | 0 | 0 | $0 |
| Jean-Luc M Lemercier | — | 7 de Julho de 2024 F | 184.686 | 0 | 0 | $0 |
| Robert W.A. Sellers | — | 11 de Maio de 2024 F | 17.081 | 0 | 0 | $0 |
| Michael A Mussallem | — | 2 de Maio de 2024 M | 4.486 | 0 | 0 | $0 |
| Martha H. Marsh | — | 12 de Maio de 2023 A | 31.880 | 0 | 0 | $0 |
| Huimin Wang | — | 8 de Julho de 2022 M | 99.381 | 0 | 0 | $0 |
| William J Link PHD | — | 8 de Maio de 2020 A | 11.349 | 0 | 0 | $0 |
| Wesley W Von Schack | — | 1 de Agosto de 2019 S | 8.000 | 0 | 0 | $0 |
| Patrick B Verguet | — | 31 de Maio de 2017 M | 129.137 | 0 | 0 | $0 |
| Randall J Nelson | — | 30 de Setembro de 2003 A | — | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 1 participação
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Pessoa de relato não divulgada | 5 de Abril de 2001 | — | Declaração inicial | Campanha no conselho | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 180 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IHI · iShares Trust | 4,29% | 1.607.851 SH | 8 de Agosto de 2026 | Diário |
| GDOC · Goldman Sachs ETF Trust | 2,98% | 6.939 NS | 31 de Maio de 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2,11% | 10.000 NS | 31 de Maio de 2026 | N-PORT |
| ANEW · ProShares Trust | 2,02% | 1.801 NS | 31 de Maio de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,83% | 2.435 NS | 30 de Abril de 2026 | N-PORT |
| PJBF · PGIM ETF Trust | 1,75% | 2.374 NS | 29 de Maio de 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1,75% | 10.488 NS | 31 de Maio de 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,58% | 137.940 SH | 8 de Agosto de 2026 | Diário |
| VOT · VANGUARD INDEX FUNDS | 1,14% | 4.411.246 SH | 8 de Agosto de 2026 | Diário |
| ALTL · Pacer Funds Trust | 0,94% | 10.780 NS | 30 de Abril de 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 0,93% | 4.325 NS | 30 de Abril de 2026 | N-PORT |
| SDG · iShares Trust | 0,90% | 17.447 SH | 8 de Agosto de 2026 | Diário |
| FFND · Northern Lights Fund Trust II | 0,88% | 10.459 NS | 31 de Maio de 2026 | N-PORT |
| IYH · iShares Trust | 0,83% | 341.366 SH | 8 de Agosto de 2026 | Diário |
| BKDV · BNY Mellon ETF Trust II | 0,81% | 134.666 NS | 30 de Abril de 2026 | N-PORT |
| NULV · Nushares ETF Trust | 0,79% | 197.378 NS | 30 de Abril de 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0,79% | 22.410 NS | 30 de Abril de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,78% | 267.514 NS | 30 de Abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,77% | 1.733.147 SH | 8 de Agosto de 2026 | Diário |
| NULC · Nushares ETF Trust | 0,75% | 5.090 NS | 30 de Abril de 2026 | N-PORT |
| RXL · ProShares Trust | 0,73% | 6.052 NS | 31 de Maio de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,70% | 11.571 NS | 30 de Abril de 2026 | N-PORT |
| IMCG · iShares Trust | 0,66% | 301.692 SH | 8 de Agosto de 2026 | Diário |
| IXJ · iShares Trust | 0,65% | 302.050 SH | 8 de Agosto de 2026 | Diário |
| TEC · Harbor ETF Trust | 0,61% | 491 NS | 30 de Abril de 2026 | N-PORT |
| FWD · AB Active ETFs, Inc. | 0,56% | 187.544 NS | 31 de Maio de 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0,56% | 4.857 NS | 30 de Abril de 2026 | N-PORT |
| BRNY · EA Series Trust | 0,54% | 35.555 NS | 30 de Abril de 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,53% | 24.654 NS | 31 de Maio de 2026 | N-PORT |
| SUSA · iShares Trust | 0,51% | 237.552 SH | 8 de Agosto de 2026 | Diário |
| VO · VANGUARD INDEX FUNDS | 0,50% | 12.477.902 SH | 8 de Agosto de 2026 | Diário |
| IWS · iShares Trust | 0,49% | 860.071 SH | 8 de Agosto de 2026 | Diário |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,42% | 44.305 NS | 30 de Abril de 2026 | N-PORT |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0,40% | 193.493 NS | 30 de Abril de 2026 | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 3.768 NS | 30 de Abril de 2026 | N-PORT |
| IWR · iShares Trust | 0,36% | 2.320.860 SH | 8 de Agosto de 2026 | Diário |
| IMCB · iShares Trust | 0,34% | 63.843 SH | 8 de Agosto de 2026 | Diário |
| JGLO · J.P. Morgan Exchange-Traded Fund Tr… | 0,34% | 286.558 NS | 30 de Abril de 2026 | N-PORT |
| EVUS · iShares Trust | 0,31% | 12.935 SH | 8 de Agosto de 2026 | Diário |
| NBCR · Neuberger Berman ETF Trust | 0,30% | 30.404 NS | 31 de Maio de 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,29% | 156.342 SH | 8 de Agosto de 2026 | Diário |
| XOEF · iShares Trust | 0,28% | 720 SH | 8 de Agosto de 2026 | Diário |
| ESUM · Strategy Shares | 0,27% | 5.033 NS | 30 de Abril de 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,27% | 189.108 NS | 30 de Abril de 2026 | N-PORT |
| WINN · Harbor ETF Trust | 0,24% | 31.226 NS | 30 de Abril de 2026 | N-PORT |
| DEUS · DBX ETF Trust | 0,24% | 7.428 NS | 29 de Maio de 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 887 NS | 30 de Abril de 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0,22% | 15.544 NS | 30 de Abril de 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 0,22% | 7.122 NS | 31 de Março de 2026 | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0,21% | 42.168 NS | 31 de Maio de 2026 | N-PORT |